American Regent Animal Health, a division of American Regent, Inc., manufacturer of Adequan® i.m. (polysulfated glycosaminoglycan) for horses, announces a new partnership with Animalcare Group plc to relaunch Adequan i.m. in Europe.
Through the exclusive distribution agreement with American Regent Animal Health, Animalcare Group plc will work toward relaunching Adequan i.m. in Europe and selected markets following necessary regulatory approvals. Adequan i.m. has been unavailable for several years in Europe due to a supply issue that has now been fully resolved.
“We are excited to be working with American Regent Animal Health to bring this important product back to the market and look forward to relaunching it following necessary European regulatory review,” says Jenny Winter, CEO of Animalcare Group plc.
“The Animalcare partnership is an important first step in returning Adequan i.m. to veterinarians outside of North America,” said Andy Ferrigno, Head of Commercial Development for American Regent Animal Health. “We are working diligently with the team at Animalcare and regulatory officials toward a smooth relaunch in Europe, but we still have some work to do. A more definitive timeline for relaunch in Europe will be provided in the coming months.”
Adequan i.m. has been marketed in the United States for 30 years for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Important Safety Information
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, visit www.adequan.com.
About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
About Animalcare Group plc
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition. For more information, visit www.animalcaregroup.co.uk.
